title: Liposomes as vehicles for targeted therapy of cancer. Part 2: clinical development.
authors.affiliation: ICRF Oncology Unit, Imperial College of Science, Technology and Medicine, Hammersmith Hospital, London, UK. Harrington.Kevin@mayo.edu
authors.forename: K J
authors.initials: KJ
authors.lastname: Harrington
authors.forename: C R
authors.initials: CR
authors.lastname: Lewanski
authors.forename: J S
authors.initials: JS
authors.lastname: Stewart
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001682:Biological Availability; D002945:Cisplatin / Q000008:administration & dosage / Q000493:pharmacokinetics; D002986:Clinical Trials as Topic; D003630:Daunorubicin / Q000008:administration & dosage / Q000493:pharmacokinetics; D004317:Doxorubicin / Q000008:administration & dosage / Q000493:pharmacokinetics; D004337:Drug Carriers; D006801:Humans; D008081:Liposomes; D009369:Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D004337:Drug Carriers; D008081:Liposomes; D004317:Doxorubicin; D002945:Cisplatin; D003630:Daunorubicin